NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 53 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $913 | -91.2% | 1,100 | -92.6% | 0.00% | – |
| Q1 2023 | $10,434 | -6.1% | 14,905 | -31.6% | 0.00% | – |
| Q4 2022 | $11,112 | +11.1% | 21,789 | +50.3% | 0.00% | – |
| Q3 2022 | $10,000 | +900.0% | 14,500 | +1218.2% | 0.00% | – |
| Q2 2022 | $1,000 | -50.0% | 1,100 | 0.0% | 0.00% | – |
| Q1 2022 | $2,000 | -96.9% | 1,100 | -91.7% | 0.00% | – |
| Q4 2021 | $64,000 | +113.3% | 13,333 | +222.0% | 0.00% | – |
| Q3 2021 | $30,000 | -21.1% | 4,141 | +1.7% | 0.00% | – |
| Q2 2021 | $38,000 | -91.7% | 4,071 | -89.1% | 0.00% | – |
| Q1 2021 | $458,000 | +1377.4% | 37,200 | +1594.0% | 0.00% | – |
| Q4 2020 | $31,000 | -53.0% | 2,196 | -59.8% | 0.00% | – |
| Q3 2020 | $66,000 | -72.3% | 5,465 | -62.0% | 0.00% | – |
| Q2 2020 | $238,000 | +221.6% | 14,378 | +121.7% | 0.00% | – |
| Q1 2020 | $74,000 | +51.0% | 6,486 | +62.2% | 0.00% | – |
| Q4 2019 | $49,000 | +250.0% | 4,000 | -21.0% | 0.00% | – |
| Q3 2019 | $14,000 | – | 5,061 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,386,300 | $19,547,000 | 2.55% |
| EcoR1 Capital, LLC | 3,122,704 | $44,030,000 | 2.37% |
| Redmile Group, LLC | 4,131,869 | $58,259,000 | 0.70% |
| Boxer Capital, LLC | 1,501,058 | $21,165,000 | 0.68% |
| HighVista Strategies LLC | 69,727 | $983,000 | 0.63% |
| Baker Brothers Advisors | 3,821,740 | $53,887,000 | 0.20% |
| Highland Private Wealth Management | 93,998 | $1,326,000 | 0.12% |
| Sio Capital Management, LLC | 38,312 | $540,000 | 0.11% |
| Point72 Asset Management, L.P. | 1,195,725 | $16,860,000 | 0.08% |
| Granahan Investment Management | 246,299 | $3,473,000 | 0.08% |